Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis

Nephrology Dialysis Transplantation

Volumn 24, Issue 11, 2009, Pages 3454-3460

  Carrero, Juan Jesús ^a   Hua, Xiang ^c   Stenvinkel, Peter ^a   Qureshi, Abdul Rashid ^a   Heimbürger, Olof ^a   Bárány, Peter ^a   Lindholm, Bengt ^b   Frostegrd, Johan ^c  

^a Division of Occupational Medicine   (Sweden)

^b Department of Clinical Science Intervention and Technology ^*  (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Atherosclerosis; Haemodialysis; IL 6; Inflammation; Phosporylcholine

Indexed keywords

IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6; PHOSPHORYLCHOLINE; IMMUNOGLOBULIN M;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; BLOOD; CHRONIC KIDNEY FAILURE; IMMUNOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RISK;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; IMMUNOGLOBULIN M; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHORYLCHOLINE; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK;

EID: 73949131809     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp309     Document Type: Article

References (35)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047
2. Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008; 371: 2173-2182
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119
4. Foley RN, Guo H, Snyder JJ, et al. Septicemia in the united states dialysis population, 1991 to 1999. J Am Soc Nephrol 2004; 15: 1038-1045
5. Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-521
6. Binder CJ, Chang MK, Shaw PX, et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218-1226
7. Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145: 33-43
8. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004; 22: 361-403
9. Frostegard J, Nilsson J, Haegerstrand A, et al. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line u937. Proc Natl Acad Sci USA 1990; 87: 904-908
10. Berliner JA, Territo MC, Sevanian A, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990; 85: 1260-1266
11. Frostegard J, Wu R, Giscombe R, et al. Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb 1992; 12: 461-467
12. Frostegard J, Huang YH, Ronnelid J, et al. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol 1997; 17: 963-968
13. Heery JM, Kozak M, Stafforini DM, et al. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 1995; 96: 2322-2330
14. Subbanagounder G, Leitinger N, Shih PT, et al. Evidence that phos-pholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis: in vitro and in vivo inhibition by web 2086. Circ Res 1999; 85: 311-318
15. Su J, Georgiades A, Wu R, et al. Antibodies of IgM subclass to phos-phorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 2006; 188: 160-166
16. Sjoberg BG, Su J, Dahlbom I, et al. Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis 2009; 203: 528-532
17. Carrero JJ, Qureshi AR, Axelsson J, et al. Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 2007; 85: 695-701
18. Davies SJ, Phillips L, Naish PF, et al. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17: 1085-1092
19. Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 1987; 11: 8-13
20. Frostegard J, Tao W, Georgiades A, et al. Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from new guinea. Nutr Metab (Lond) 2007; 4: 7
21. Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148
22. Zoccali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 2006; 17: S169-S173
23. Carrero JJ, Ortiz A, Qureshi AR, et al. Additive effects of soluble tweak and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 110-118
24. Metry G, Stenvinkel P, Qureshi AR, et al. Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. Eur J Clin Invest 2008; 38: 804-811
25. Carrero JJ, Stenvinkel P. Of persistent inflammation as a catalyst for other risk factors in chronic kidney disease; a hypothesis proposal. Clin J Am Soc Nephrol 2009 (In press)
26. Harnett W, Harnett MM. Phosphorylcholine: friend or foe of the immune system? Immunol Today 1999; 20: 125-129
27. Briles DE, Forman C, Hudak S, et al. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med 1982; 156: 1177-1185
28. Lindeberg S, Lundh B. Apparent absence of stroke and ischaemic heart disease in a traditional melanesian island: a clinical study in Kitava. J Intern Med 1993; 233: 269-275
29. Su J, Hua X, Concha H, et al. Natural antibodies against phosphoryl-choline as potential protective factors in SLE. Rheumatology (Oxford) 2008
30. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086-1095
31. Caligiuri G, Khallou-Laschet J, Vandaele M, et al. Phosphorylcholine- targeting immunization reduces atherosclerosis. J Am Coll Cardiol 2007; 50: 540-546
32. Faria-Neto JR, Chyu KY, Li X, et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006; 189: 83-90
33. Binder CJ, Horkko S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9: 736-743
34. Boullier A, Gillotte KL, Horkko S, et al. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem 2000; 275: 9163-9169
35. Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105: 1049-1056